Beatriz Eda de Oliveira Isídio

Beatriz Eda de Oliveira Isídio

Auto-generated profile, based on publicly available information

Beatriz Eda de Oliveira Isídio

Laboratory of Molecular Studies and Experimental Therapy, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, PE, Brazil

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2026 in Exploration of Targeted Anti-tumor Therapy
Verified
Journal Article
Open access
PDF file
BIBeatriz Eda de Oliveira Isídio
Beatriz Eda de Oliveira Isídio
PFPedro Henrique Bezerra Fontes
Pedro Henrique Bezerra Fontes
GSGabriel Rômulo Parente da Silva
Gabriel Rômulo Parente da Silva
SLStephanie Loureiro Leão
Stephanie Loureiro Leão
BMBianca de França São Marcos
Bianca de França São Marcos
Antonio Carlos de FreitasAntonio Carlos de Freitas
Antonio Carlos de Freitas
Aim: Breast cancer is the most prevalent malignant tumor among women. Human papillomavirus (HPV) has been detected in breast tumors since the 1990s, and beyond its oncogenic potential, therapy resistance driven by viral immune evasion in non-anogenital tumors, such as oropharyngeal cancers, highlights the need to investigate viral activity in breast tissues. Among high-risk HPV types, HPV16 is one of the most prevalent and exhibits the highest carcinogenic potential. Therefore, this study aimed to evaluate the expression of HPV16 oncogenes E5, E6, and E7 in breast tumors, as well as the modulation of the PI3K/AKT/mTOR signaling pathway associated with viral activity. Methods: A total of 92 breast cancer patients were included after Ethics Committee approval. Clinical data were obtained from medical records. RNA was extracted from formalin-fixed, paraffin-embedded tissues and reverse-transcribed into cDNA. Transcripts of HPV oncogenes (E5, E6, and E7), components of the PI3K/AKT/mTOR pathway, and regulatory genes (EGFR and PTEN) were quantified by RT-qPCR. Gene expression levels were calculated using the ΔCt method. Results: Forty-eight samples met RNA quality criteria and were included in the expression analysis. Among these, 77.08% showed expression of at least one viral oncogene, with E5 being the most frequently expressed. The PI3K/AKT/mTOR pathway was modulated in HPV-positive samples, with increased PI3K expression and decreased mTOR expression. Notably, the high expression of E5—associated with immune evasion—combined with reduced mTOR expression suggests that HPV16 status may influence therapeutic response in breast cancer patients. Conclusions: These findings reinforce the importance of further studies investigating HPV activity in breast tumors to better understand its biological and clinical impact.